316 related articles for article (PubMed ID: 21383688)
1. KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma.
Jiffar T; Yilmaz T; Lee J; Hanna E; El-Naggar A; Yu D; Myers JN; Kupferman ME
Oncogene; 2011 Jul; 30(28):3163-73. PubMed ID: 21383688
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-induced ROS promotes mitochondrial fission and cisplatin chemosensitivity via HIF-1α/Mff regulation in head and neck squamous cell carcinoma.
Wu K; Mao YY; Chen Q; Zhang B; Zhang S; Wu HJ; Li Y
Cell Oncol (Dordr); 2021 Oct; 44(5):1167-1181. PubMed ID: 34460078
[TBL] [Abstract][Full Text] [Related]
3. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
[TBL] [Abstract][Full Text] [Related]
4. Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance.
Liu S; Ren B; Gao H; Liao S; Zhai YX; Li S; Su XJ; Jin P; Stroncek D; Xu Z; Zeng Q; Li Y
J Transl Med; 2017 Sep; 15(1):189. PubMed ID: 28877725
[TBL] [Abstract][Full Text] [Related]
5. Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma.
Osman AA; Arslan E; Bartels M; Michikawa C; Lindemann A; Tomczak K; Yu W; Sandulache V; Ma W; Shen L; Wang J; Singh AK; Frederick MJ; Spencer ND; Kovacs J; Heffernan T; Symmans WF; Rai K; Myers JN
Clin Cancer Res; 2023 Apr; 29(7):1344-1359. PubMed ID: 36689560
[TBL] [Abstract][Full Text] [Related]
6. A cisplatin-resistant head and neck cancer cell line with cytoplasmic p53(mut) exhibits ATP-binding cassette transporter upregulation and high glutathione levels.
Tonigold M; Rossmann A; Meinold M; Bette M; Märken M; Henkenius K; Bretz AC; Giel G; Cai C; Rodepeter FR; Beneš V; Grénman R; Carey TE; Lage H; Stiewe T; Neubauer A; Werner JA; Brendel C; Mandic R
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1689-704. PubMed ID: 24913304
[TBL] [Abstract][Full Text] [Related]
7. A novel role for BDNF-TrkB in the regulation of chemotherapy resistance in head and neck squamous cell carcinoma.
Lee J; Jiffar T; Kupferman ME
PLoS One; 2012; 7(1):e30246. PubMed ID: 22276165
[TBL] [Abstract][Full Text] [Related]
8. cRGD peptide installation on cisplatin-loaded nanomedicines enhances efficacy against locally advanced head and neck squamous cell carcinoma bearing cancer stem-like cells.
Miyano K; Cabral H; Miura Y; Matsumoto Y; Mochida Y; Kinoh H; Iwata C; Nagano O; Saya H; Nishiyama N; Kataoka K; Yamasoba T
J Control Release; 2017 Sep; 261():275-286. PubMed ID: 28666729
[TBL] [Abstract][Full Text] [Related]
9. Lupeol suppresses cisplatin-induced nuclear factor-kappaB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model.
Lee TK; Poon RT; Wo JY; Ma S; Guan XY; Myers JN; Altevogt P; Yuen AP
Cancer Res; 2007 Sep; 67(18):8800-9. PubMed ID: 17875721
[TBL] [Abstract][Full Text] [Related]
10. Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.
Gadhikar MA; Sciuto MR; Alves MV; Pickering CR; Osman AA; Neskey DM; Zhao M; Fitzgerald AL; Myers JN; Frederick MJ
Mol Cancer Ther; 2013 Sep; 12(9):1860-73. PubMed ID: 23839309
[TBL] [Abstract][Full Text] [Related]
11. Stable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in vitro, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models.
Sobral LM; Sousa LO; Coletta RD; Cabral H; Greene LJ; Tajara EH; Gutkind JS; Curti C; Leopoldino AM
Mol Cancer; 2014 Feb; 13():32. PubMed ID: 24555657
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of IGF2 is associated with an acquired resistance for cis-diamminedichloroplatinum in human head and neck squamous cell carcinoma.
Ogawa T; Ogawa K; Shiga K; Furukawa T; Nagase H; Hashimoto S; Kobayashi T; Horii A
Eur Arch Otorhinolaryngol; 2010 Oct; 267(10):1599-606. PubMed ID: 20443017
[TBL] [Abstract][Full Text] [Related]
13. Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors.
Cullen KJ; Newkirk KA; Schumaker LM; Aldosari N; Rone JD; Haddad BR
Cancer Res; 2003 Dec; 63(23):8097-102. PubMed ID: 14678959
[TBL] [Abstract][Full Text] [Related]
14. Expression of DNA translesion synthesis polymerase η in head and neck squamous cell cancer predicts resistance to gemcitabine and cisplatin-based chemotherapy.
Zhou W; Chen YW; Liu X; Chu P; Loria S; Wang Y; Yen Y; Chou KM
PLoS One; 2013; 8(12):e83978. PubMed ID: 24376779
[TBL] [Abstract][Full Text] [Related]
15. A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Chung CH; Lee JW; Slebos RJ; Howard JD; Perez J; Kang H; Fertig EJ; Considine M; Gilbert J; Murphy BA; Nallur S; Paranjape T; Jordan RC; Garcia J; Burtness B; Forastiere AA; Weidhaas JB
Ann Oncol; 2014 Nov; 25(11):2230-2236. PubMed ID: 25081901
[TBL] [Abstract][Full Text] [Related]
16. Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients.
Akervall J; Guo X; Qian CN; Schoumans J; Leeser B; Kort E; Cole A; Resau J; Bradford C; Carey T; Wennerberg J; Anderson H; Tennvall J; Teh BT
Clin Cancer Res; 2004 Dec; 10(24):8204-13. PubMed ID: 15623595
[TBL] [Abstract][Full Text] [Related]
17. Dynamic cellular and molecular modulations of diabetes mediated head and neck carcinogenesis.
Liu CJ; Chang WJ; Chen CY; Sun FJ; Cheng HW; Chen TY; Lin SC; Li WC
Oncotarget; 2015 Oct; 6(30):29268-84. PubMed ID: 26337468
[TBL] [Abstract][Full Text] [Related]
18. Tumor-associated fibroblast-conditioned medium induces CDDP resistance in HNSCC cells.
Steinbichler TB; Metzler V; Pritz C; Riechelmann H; Dudas J
Oncotarget; 2016 Jan; 7(3):2508-18. PubMed ID: 26497215
[TBL] [Abstract][Full Text] [Related]
19. The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.
Hagege A; Ambrosetti D; Boyer J; Bozec A; Doyen J; Chamorey E; He X; Bourget I; Rousset J; Saada E; Rastoin O; Parola J; Luciano F; Cao Y; Pagès G; Dufies M
Theranostics; 2021; 11(19):9571-9586. PubMed ID: 34646387
[No Abstract] [Full Text] [Related]
20. Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma.
Stanam A; Gibson-Corley KN; Love-Homan L; Ihejirika N; Simons AL
Oncotarget; 2016 Nov; 7(46):76087-76100. PubMed ID: 27738319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
